Top 8 Companies in the Global Bacterial Disease Diagnostics Market

The global bacterial disease diagnostics market was valued at USD 3.1 billion in 2023 due to the rising prevalence of bacterial infections across the globe. The market is expected to grow at a CAGR of 7.10% during the forecast period 2024-2032 and attain a market value of USD 5.8 billion by 2032.

Bacterial disease diagnostics are essential for detecting and identifying bacterial pathogens in clinical samples to determine the presence and type of infection. Healthcare providers employ various diagnostic methods to ensure accurate results and guide treatment decisions. These methods typically involve collecting samples from patients and using techniques such as bacterial culture, biochemical tests, DNA amplification via polymerase chain reaction (PCR), and serological tests for antibodies or antigens. Imaging methods, including X-rays and CT scans, are also used to assess the extent of infection, especially in organs like the lungs.

Recent technological advancements are significantly driving the market’s growth. Next-generation sequencing (NGS) provides an in-depth examination of bacterial genomes, enabling precise identification of pathogens. PCR plays a critical role in detecting bacterial DNA and reducing diagnostic time. Additionally, artificial intelligence (AI) and machine learning are enhancing data analysis, facilitating quicker and more accurate identification of bacterial infections. For example, in December 2022, researchers from Stanford Medicine developed a blood test that can effectively distinguish between bacterial and viral infections, adhering to World Health Organization guidelines. Furthermore, in June 2024, a Dutch scientist was nominated as a finalist for the Young Inventors Prize for creating a portable AI-powered tool for diagnosing bacterial infections.

The slow diagnosis of common bacterial infections contributes to a significant number of global deaths. Efforts to develop faster, AI-assisted diagnostic tools aim to address this issue, improving treatment outcomes and accelerating decision-making in clinical settings. This push for rapid detection is expected to propel market growth in the forecast period.

Major Companies Shaping the Bacterial Disease Diagnostics Market in 2024

1.    F. Hoffmann-La Roche Ltd:

F. Hoffmann-La Roche Ltd is a global leader in pharmaceuticals and diagnostics. Their portfolio includes treatments for oncology, immunology, infectious diseases, and neuroscience, along with diagnostic solutions. Roche’s diagnostics division offers advanced systems and reagents for medical testing, driving progress in precision medicine, and personalised care.

2.    Thermo Fisher Scientific Inc:

Thermo Fisher Scientific Inc. is a leading provider of laboratory instruments, reagents, and services. Their product portfolio spans analytical instruments, lab supplies, diagnostics, and life sciences solutions. For instance, in February 2024, the company expanded its PPD clinical research services by adding mycoplasma and biosafety testing capabilities to its GMP lab in Middleton, Wisconsin. This enhancement strengthens its analytical testing services, ensuring biopharmaceutical products are free of contaminants. This new development will support the diagnostics of bacterial diseases by improving safety and reliability in drug production, positively impacting the market by increasing customer trust and driving demand for advanced diagnostic services in the forecast period.

3.    Abbott Laboratories:

Abbott, a global leader in healthcare technology, is known for its diagnostic solutions and medical devices. The company is heavily involved in various disease diagnostics, including bacterial infections. For instance, in February 2024, Abbott partnered with Fujirebio to develop a research-use-only (RUO) neurofilament-light chain (Nf-L) biomarker assay for Abbott’s Alinity i system. This assay, aimed at advancing neurological research, is expected to enhance diagnostic capabilities for diseases like multiple sclerosis and Alzheimer’s by 2025. While the collaboration primarily focuses on neurology, it reflects Abbott’s continuous innovation, which will likely influence its bacterial diagnostics portfolio as well. This strategic move is poised to strengthen Abbott's leadership in diagnostic innovation, including its contributions to bacterial disease detection, in the coming years.

4.    Becton, Dickinson and Company

BD (Becton, Dickinson and Company) is a leading global medical technology company specialising in diagnostics, medical devices, and biosciences. BD’s portfolio includes products for infection prevention, diagnostics, and medication management, particularly in the area of bloodstream infections and sepsis. In March 2024, BD partnered with The Great Orchestra of Christmas Charity (GOCC) in Poland to expand testing for bloodstream infections (BSIs) and sepsis management. This collaboration aims to provide over 150 healthcare facilities with advanced diagnostic tools, including the BD Bruker MALDI Biotyper Sirius IVD System and BD Phoenix M50 Systems. This move will significantly enhance diagnostic capabilities in Poland, driving growth in the bacterial disease diagnostics market by improving infection detection and treatment efficiency. The expanded access to BD’s diagnostic technologies will support early diagnosis and improve sepsis management, fostering better patient outcomes in the region. This partnership is expected to drive the adoption of advanced diagnostic systems in Eastern Europe, boosting the market growth in the forecast period.

5.    Siemens Healthineers AG

Siemens Healthineers, headquartered in Erlangen, Germany, is a leading global medical technology company focused on providing diagnostic solutions, medical imaging, and laboratory diagnostics. With expertise in the bacterial disease diagnostics market, Siemens offers advanced solutions to improve patient outcomes. For instance, in November 2023, Siemens Healthineers entered into a contract with the National Institute of Allergy and Infectious Diseases to develop a next-generation diagnostic tool for rapid sepsis detection. This tool aims to identify bacterial and fungal infections and their antibiotic resistance within six hours, a critical innovation poised to enhance sepsis diagnosis and treatment in the coming years, improving patient survival rates and addressing urgent clinical needs.

6.    bioMerieux, Inc.

bioMérieux is a global leader in in vitro diagnostics, with a strong portfolio of diagnostic solutions targeting infectious diseases, including bacterial diagnostics. For instance, in February 2024, bioMérieux entered into a strategic research collaboration with the US FDA’s CFSAN to develop innovative tools for combating food-borne pathogens. This partnership focuses on improving pathogen detection and microbial characterisation systems, which will have a significant impact on the bacterial disease diagnostics market, enhancing food safety and driving advancements in pathogen detection technologies over the forecast period.

7.    Cepheid Inc. (a Danaher company)

Cepheid Inc., a Danaher company, is a pioneer in molecular diagnostics, offering real-time PCR systems for a wide range of applications. The company’s product portfolio includes diagnostic solutions for infectious diseases, cancer, and genetic disorders, providing clinicians with rapid results to make informed decisions in critical care environments.

8.    Hologic, Inc.

Hologic, Inc., headquartered in Marlborough, Massachusetts, is a global leader in molecular diagnostics, specialising in women’s health, and a broad range of infectious disease diagnostics. For instance, in October  2021, Hologic launched the Novodiag system in Europe, following its acquisition of Mobidiag Oy. This fully automated molecular diagnostic solution enables fast, on-demand testing for infectious diseases and antimicrobial resistance. The system’s ability to identify multiple pathogens in a single sample is poised to significantly enhance bacterial disease diagnostics, improving rapid testing and targeting high-risk patients. The news highlights Hologic’s growing footprint in the European market, with its advanced diagnostic solutions likely to drive demand in the forecast period.